InvestorsHub Logo
Followers 0
Posts 43
Boards Moderated 0
Alias Born 02/09/2013

Re: biopharm post# 198688

Saturday, 12/06/2014 12:32:54 PM

Saturday, December 06, 2014 12:32:54 PM

Post# of 346654



"Most researchers believe that the key to expanding immunotherapy lies in combination treatments.
A 53-patient Bristol-Myers study combining Yervoy and nivolumab resulted in a two-year melanoma survival rate of 79%, but that came at a cost of serious side effects."

Bavituximab?

http://online.wsj.com/articles/cancers-super-survivors-how-immunotherapy-is-transforming-oncology-1417714379?tesla=y
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News